- Home
- GAIN vs REPL Comparison
GAIN vs REPL Comparison
Compare GAIN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAIN
- REPL
- Stock Information
- Founded
- GAIN 2005
- REPL 2015
- Country
- GAIN United States
- REPL United States
- Employees
- GAIN N/A
- REPL N/A
- Industry
- GAIN Finance: Consumer Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- GAIN Finance
- REPL Health Care
- Exchange
- GAIN Nasdaq
- REPL Nasdaq
- Market Cap
- GAIN 551.1M
- REPL 547.0M
- IPO Year
- GAIN 2005
- REPL 2018
- Fundamental
- Price
- GAIN $14.01
- REPL $9.15
- Analyst Decision
- GAIN Buy
- REPL Buy
- Analyst Count
- GAIN 2
- REPL 9
- Target Price
- GAIN $14.00
- REPL $12.00
- AVG Volume (30 Days)
- GAIN 131.5K
- REPL 8.5M
- Earning Date
- GAIN 11-04-2025
- REPL 11-06-2025
- Dividend Yield
- GAIN 15.73%
- REPL N/A
- EPS Growth
- GAIN 136.17
- REPL N/A
- EPS
- GAIN 2.49
- REPL N/A
- Revenue
- GAIN $97,742,000.00
- REPL N/A
- Revenue This Year
- GAIN $6.54
- REPL N/A
- Revenue Next Year
- GAIN $4.49
- REPL N/A
- P/E Ratio
- GAIN $5.61
- REPL N/A
- Revenue Growth
- GAIN 6.86
- REPL N/A
- 52 Week Low
- GAIN $11.42
- REPL $2.68
- 52 Week High
- GAIN $15.34
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- GAIN 55.06
- REPL 62.07
- Support Level
- GAIN $13.80
- REPL $7.99
- Resistance Level
- GAIN $14.04
- REPL $9.57
- Average True Range (ATR)
- GAIN 0.24
- REPL 0.73
- MACD
- GAIN 0.01
- REPL -0.15
- Stochastic Oscillator
- GAIN 77.12
- REPL 38.22
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.